Setmelanotide is a medication that acts on the melanocortin-4 receptor (MC4R) for the treatment of severe obesity caused by genetic disorders, including deficiency of proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR). This activity reviews the indication, mechanism of action, adverse events, contradiction, monitoring, and toxicity of setmelanotide therapy, which can provide essential information to the clinical team members responsible for managing the care of patients with severe obesity and its related conditions.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/148945
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Ambulatory/Outpatient, Bariatric Surgery, Endocrinology, Diabetes, and Metabolism, General Operative Anesthesia, General Pediatrics, Internal Medicine, Molecular Genetic Pathology, Pediatric Endocrinology
Subscribe
Login
0 Comments
Oldest